CapsoVision, Inc. (CV) vs Relmada Therapeutics, Inc. (RLMD)
A side-by-side comparison of CapsoVision, Inc. and Relmada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CV
CapsoVision, Inc.
$6.54HealthcareDelayed quote: Oct 6, 2026, 3:19 PM EDT
RLMD
Relmada Therapeutics, Inc.
$3.29HealthcareDelayed quote: Oct 6, 2026, 3:15 PM EDT
Total return — CV vs RLMD
growth of $100 · dividends reinvested · last 1yCV +88.3% (+88.3%/yr)RLMD +479.7% (+479.7%/yr)RLMD compounded faster over this window
CV RLMD
CV vs RLMD: by the numbers
- •RLMD is the larger company ($346M vs $327M market cap).
- •Both run net losses; RLMD's is the smaller (0.00% vs -214.74% net margin).
Metrics side by side
Valuation
| Metric | CV | RLMD |
|---|---|---|
| P/S ratio | 23.51 | N/A |
| P/B ratio | 24.80 | 1.67 |
Profitability
| Metric | CV | RLMD |
|---|---|---|
| Gross margin | 50.88% | 0.00% |
| Operating margin | -188.25% | 0.00% |
| Net margin | -214.74% | 0.00% |
| ROE | -226.56% | -29.98% |
| ROIC | -164.32% | -30.78% |
Growth (annualized)
| Metric | CV | RLMD |
|---|---|---|
| Total return CAGR (5Y) | N/A | -7.68% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.